Lilly v. FDA: Court Vacates Retatrutide Drug Classification

On September 30, 2025, a federal court in Indiana vacated the FDA’s decision to regulate Eli Lilly’s investigational obesity drug retatrutide (LY3437943) as a “drug” rather than a “biological product.” Judge Tanya Walton Pratt ruled that the FDA’s narrow reading of the statutory phrase “analogous to a protein” was arbitrary and capricious, and remanded the question back to the agency. In February 2026 Lilly appealed, asking the Seventh Circuit to go further and order the FDA to classify retatrutide as a biologic outright. The ruling itself is not about whether retatrutide works. It is about which regulatory bucket the molecule lives in, and that bucket determines whether compounding pharmacies can legally produce retatrutide once a brand version arrives. Below: what the court actually decided, why Lilly is fighting for the seemingly counterintuitive biologic classification, what changed for the program in December 2025 when TRIUMPH-4 read out, and what it means for anyone currently watching the retatrutide market.
Table of Contents
- What the court actually ruled
- Why a “drug vs. biologic” label matters
- Why Lilly wants retatrutide called a biologic
- The February 2026 appeal
- What changes for retatrutide compounding right now
- Where this fits — including the December TRIUMPH-4 readout
- What we are watching next
- References
What the court actually ruled
The case is Eli Lilly & Co. v. FDA, No. 1:24-cv-01503 (S.D. Ind.). Lilly sued the FDA in 2024 after the agency told the company that retatrutide would be regulated as a drug, not a biological product. On September 30, 2025, the district court issued a 47-page opinion that did two things at once.
First, the court agreed with the FDA that retatrutide does not meet the agency’s regulatory definition of a “protein.” That definition, finalized in 2020, requires an alpha-amino-acid polymer with a specific, defined sequence greater than 40 amino acids. Retatrutide is built from a 39-residue alpha-amino-acid chain with a second short chain covalently attached, at least one residue of which is not an alpha amino acid. Under the bright-line “protein” definition, that comes up short.
Second, and this is the part that drove the headlines, the court rejected the FDA’s interpretation of the residual “analogous to a protein” category. The Biologics Price Competition and Innovation Act of 2009 includes that catch-all phrase specifically so molecules that are protein-like but not technically “proteins” can still be regulated as biologics. The FDA’s position has been that anything failing the 40-alpha-amino-acid threshold also fails the analogous category by definition. Judge Pratt called that a “bright line” that “flouts the statutory text and sidesteps congressional intent.” The decision was set aside and remanded to the FDA to identify, in a uniform fashion, what the defining feature of an analogous product actually is.
Importantly, the court did not declare retatrutide to be a biologic. It told the FDA to redo the analysis with a defensible definition.
Why a “drug vs. biologic” label matters
Two reasons, and both have downstream effects on patients.
Approval pathway. Drugs are approved under the Federal Food, Drug, and Cosmetic Act through a New Drug Application. Biologics are licensed under the Public Health Service Act through a Biologics License Application. The clinical evidence bar is similar, but the post-approval landscape differs. Drugs face generic competition under Hatch-Waxman. Biologics face biosimilar competition under the BPCIA, which carries a longer exclusivity window and a more involved technical comparison process.
Compounding eligibility. This is where retatrutide gets interesting for our readers. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies can produce drugs from bulk substances that appear on a specific FDA list or are components of approved drugs, subject to other conditions. Biologics are subject to additional layers and are functionally much harder, and in many cases impossible, to compound through the 503A framework. Recent FDA guidance has reinforced that compounded copies of approved biologics are not permitted under 503A.
In other words, the bucket determines whether, after retatrutide is approved, a 503A pharmacy can lawfully prepare retatrutide vials for individual patients the way many do for tirzepatide and semaglutide during shortages.
Why Lilly wants retatrutide called a biologic
At first glance this looks backwards. Companies typically want their products to be drugs, not biologics, because the drug pathway is faster, cheaper, and gives the sponsor cleaner exclusivity. Lilly’s preference here only makes sense once you account for the compounded GLP-1 market that exploded during the 2022 to 2025 tirzepatide and semaglutide shortages.
Lilly watched roughly three years of compounded tirzepatide and semaglutide compete with Mounjaro, Zepbound, and Ozempic on price. The FDA Drug Shortage list created a window under Section 503B and Section 503A that allowed outsourcing facilities and traditional pharmacies to mass-produce compounded versions. Lilly has been clear in public filings and litigation that it wants the next-generation product to launch without that pressure. Classifying retatrutide as a biologic at the regulatory level is one route to that outcome. If the molecule is a biologic, the 503A bulk-substance pathway does not apply in the same way, and 503B outsourcing facilities have a far narrower ability to make copies even during a shortage.
The court’s September 2025 ruling did not give Lilly the biologic label outright. It told the FDA that the agency cannot reach the “not a biologic” conclusion through a definition that the court found legally indefensible. On remand, the FDA could reach the same conclusion with better reasoning, or it could reach a different one. Lilly’s appeal is an attempt to short-circuit that uncertainty.
The February 2026 appeal
On February 13, 2026, Lilly filed a notice of appeal asking the U.S. Court of Appeals for the Seventh Circuit to go further than the district court did. Lilly’s position, as reported by Endpoints News and confirmed in court filings, is that the district court should not have stopped at a remand. The company wants the appellate court to direct the FDA to classify retatrutide as a biologic, on the theory that any defensible reading of the “analogous to a protein” phrase has to include molecules like retatrutide.
As of May 2026 the appeal is in briefing and the FDA’s remand analysis is also pending. Public reporting has not yet captured a Seventh Circuit briefing schedule or any FDA remand decision. Seventh Circuit timelines for administrative-law appeals typically run 9 to 14 months from notice of appeal. The two tracks run in parallel, so an FDA decision could conceivably arrive before the appellate ruling.
What changes for retatrutide compounding right now
For the moment, almost nothing changes on the ground. Retatrutide is still investigational. There is no FDA-approved retatrutide product, the molecule has never appeared on the FDA Drug Shortage list, and retatrutide is not a bulk-listed substance under 503A. Anyone selling “compounded retatrutide” through a US telehealth platform in 2026 is operating outside the established compounding framework. That was true on September 29, 2025, the day before the district court ruling, and it is still true today.
What the litigation changes is the future. If Lilly prevails, either through the FDA’s remand decision or through the Seventh Circuit, retatrutide arrives on the market as a biologic. That makes future 503A compounded retatrutide functionally impossible. If the FDA on remand reaches the same drug-classification conclusion with a better-articulated definition, retatrutide arrives as a drug and the 503A pathway remains theoretically available, subject to the usual FDA Drug Shortage and bulk-substance constraints.
For users currently considering research-chemical retatrutide from overseas suppliers, the regulatory case does not change the underlying picture. That market exists outside FDA jurisdiction in the first place, and the classification fight is downstream of whether such material is legal for human use in the United States. It is not, and the court ruling does not affect that.
Where this fits in the bigger retatrutide timeline
The classification fight is happening in parallel with an actively maturing Phase 3 program. Two months after the district court ruling, Lilly delivered its first successful Phase 3 readout. A quick orientation as of May 2026:
- Sept 30, 2025: District court vacates FDA’s drug classification, remands for a defensible “analogous to a protein” definition.
- Dec 11, 2025 — TRIUMPH-4 topline positive. First Phase 3 readout. In 445 adults with obesity or overweight plus knee osteoarthritis, retatrutide 12 mg delivered 28.7% mean weight loss at 68 weeks (-71.2 lbs from a 248.5 lb mean baseline) and reduced WOMAC pain scores by 75.8% under the efficacy estimand. The 9 mg dose delivered 26.4% weight loss and similar pain relief. More than 1 in 8 retatrutide-treated participants were completely free of knee pain at the end of the trial. Adverse events tracked the GLP-class profile (nausea, diarrhea, constipation, vomiting), with discontinuation rates of 12.2% (9 mg) and 18.2% (12 mg) versus 4.0% on placebo. The 28.7% figure is the highest in-class result reported for any FDA-track obesity drug to date.
- Feb 13, 2026: Lilly appeals to the Seventh Circuit, asking the appellate court to direct an outright biologic classification rather than leaving the question on remand.
- 2026 readouts ahead: Per Lilly’s December 2025 guidance, seven additional Phase 3 trials are expected to complete in 2026, including TRIUMPH-1 (general obesity, the largest in the program), TRIUMPH-2 (type 2 diabetes), TRIUMPH-3 (obstructive sleep apnea), and Phase 3 cardiovascular-outcome data from the TRANSCEND program. Recent investor analyst notes have moved TRIUMPH-1 topline guidance toward late 2026 or early 2027.
- NDA or BLA filing: Lilly has guided to a 2026–2027 filing window. Which application type the company files will depend on whether the classification fight is resolved before submission, and which way it resolves.
- Earliest realistic FDA approval: Late 2027 or 2028, assuming standard review timelines and positive TRIUMPH-1 data.
For background on retatrutide’s mechanism, Phase 2 data, dosing math, and side-effect profile, see our retatrutide dosing guide.
What we are watching next
Three datapoints will move the picture meaningfully:
- The FDA’s remand analysis. The agency now has to publish a defensible standard for what makes a product “analogous” to a protein. That standard will apply far beyond retatrutide and will set the rules for the next generation of peptide therapeutics that hover near the 40-amino-acid line.
- The Seventh Circuit ruling. If the appellate court agrees with Lilly that retatrutide must be classified as a biologic, that closes the 503A compounding door for retatrutide before it opens.
- TRIUMPH-1 topline. When the general-obesity Phase 3 readout lands (Lilly’s current guidance points to late 2026 or early 2027), the BLA or NDA filing decision will be made against a known classification. If the classification fight is unresolved by then, Lilly will likely file under whichever pathway is operative and amend if needed.
We will update this page when any of those three datapoints land.
References
- Memorandum Order and Decision, Eli Lilly & Co. v. FDA, No. 1:24-cv-01503 (S.D. Ind. Sept. 30, 2025). GovInfo PDF.
- Burgess B, Perez-Sparks S, Snyder C. District Court Sets Aside FDA’s Interpretation of “Analogous” to a Protein for Purposes of the “Biological Product” Category. Goodwin Procter Life Sciences Alert, October 3, 2025. Goodwin.
- Kramer A. Lilly appeals retatrutide classification ruling in case that could impact compounders. Endpoints News, February 13, 2026. Endpoints.
- U.S. Food and Drug Administration. 21 C.F.R. § 600.3(h)(6) — definition of “protein.” Cornell LII.
- Public Health Service Act, 42 U.S.C. § 262(i)(1) — definition of “biological product.” Cornell LII.
- U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. FDA.
- U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A. FDA.
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med. 2023;389(6):514-526. NEJM.
- Eli Lilly and Company. Lilly’s triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial. Press release, December 11, 2025. Lilly Investor Relations.
- TRIUMPH-4 (NCT05931367) — A Study of Retatrutide in Participants With Obesity and Knee Osteoarthritis. ClinicalTrials.gov.
- Eli Lilly. TRIUMPH phase 3 program for retatrutide (full program listing). ClinicalTrials.gov.




